Punit was at Inovio.
They still haven't completed even one Phase 3 trial in 35 years running.
When you peddle failed dung for years, you'll never reach a Phase 3 trial.
Punit licensed the failed dung from Inovio.
Isn't it obvious that that is what he is saying?
57M shares were outstanding on July 31, 2011.
Now 3 years later, it's 250,000,000.
Punit's dilution comes fast and furious.
These are hit and run hedgies.
They are Wall Street vultures, not angels.
They sell short and cover with the discounted shares.
The annualized risk free return is huge on these deals.
10%+ for a few weeks of work (some 200% annualized) - to screw the baggies by starting a landslide in the pps.
How did the prior offering work out for you?
They are all expenses paid junkets for Dhillon and the boys.
There isn't any news that is ever presented.
The stock normally drops after these needless conferences.
I've attended some in the past.
They have lavish soirees, opening cocktail reception, three course lunches,
highly compensated guest speakers and deluxe suites.
You are on the crossroads of extinction.
Pump articles are designed for someone to take a dump.
The fundamentals are not good.
There is always news that biotech baggies are waiting for.
The pps drop is telling you that the news will be bad.
Yellen's comments are the excuse that pumpers are using to hold you in.
Other biotechs didn't take the hit that ONCS did.
The stock is not oversold, it's overvalued.
There was no panic just consistent selling of large blocks.
Could it be the insiders? Who else holds large blocks?
Sure, there could be a quick bounce if the MMs had to pick up some of the blocks.
Did you say that the run up to the .90s was irrational exuberance, exaggerated and overdone?
This is a partial return of rationality.
What changed since the .20s? More dilution.
An argument can be made that the stock should be below .20 now.
Serious comments were posted to enlighten you.
Read the "DD: What ONCS has to Offer" post or the "Wow, What a Deal" post.
Those are factual posts, not hype.
Look at the CEO's credentials. He's a political science major.
Look at his prior track record at INO, massive dilution followed by a reverse split while the pps plunged from $50 to 50 cents.
That's not emotion speaking, those are the facts.
It's a non-exclusive license. So penny is right, for all intents, it is worthless.
The part that jrl0808 cites is that if ONCS sublicenses the non-exclusive license, they would have to pay a fee and a royalty if anything is developed.
That doesn't help his case.
You are the one hyping names and credentials.
It doesn't show credibility, it shows desperation.
You keep calling those that post excerpts from SEC filings and Press Releases liars without stating what the lie is.
How desperate is that?
ONCS got a NON-EXCLUSIVE license from INO to failed technology and ONCS gave INO an EXCLUSIVE license to its technology. That leaves ONCS with NOTHING.
"We are also party to a cross-license agreement with Inovio, which we entered into concurrently with the closing of our asset acquisition. This agreement provides for the exclusive license to Inovio of rights related to certain OMS technology patents in the field of gene or nucleic acids, outside of those encoding cytokines, delivered by electroporation and for the non-exclusive cross-license by Inovio to us of rights related to certain non-OMS technology patents in the OMS field in exchange for specified sublicensing and other licensing fees and royalties."
They got a patent from a university? How meaningless is that?
Did they acquire a drug in P2, in P3?
They acquired a patent?
You can probably acquire a patent from a university for $25K.
while the scammers DUMPED.
Electroporation? Not one product approved in decades of futility and failure.